A New Wearable Technology – Chemotherapy Monitoring
Darren Roblyer, Boston University, COE
There is growing evidence that non-invasive diffuse optical measurements, which use near infrared (NIR) light to track tumor oxygenation and blood volume, can predict long term response and resistance to systemic cancer therapies in breast cancer patients. This idea has tremendous potential to change the way almost all most cancer patients are treated, providing opportunities to continuously adapt therapeutic regimens using real-time optical feedback, helping to avoid multi-drug resistance and improve overall survival. The group is exploring optical signatures of systemic therapy response and resistance in multiple organ sites and cancers including breast and osteosarcoma and have identified a growing number of relevant timepoints during presurgical (neoadjuvant) chemotherapy which correlate with long term pathologic response.